药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
2期
168-170
,共3页
急性缺血性脑梗死%银杏达莫%脉络宁%丹参酮ⅡA磺酸钠%成本-效果分析
急性缺血性腦梗死%銀杏達莫%脈絡寧%丹參酮ⅡA磺痠鈉%成本-效果分析
급성결혈성뇌경사%은행체막%맥락저%단삼동ⅡA광산납%성본-효과분석
Acute ischemic cerebral infarction%Ginkgo leaf Extract and Dipyridamole injection%Mailuoning Injection%Tanshinone ⅡA sulfonic acid Natrium injection%Cost-effectiveness analysis
目的：探讨银杏达莫、脉络宁和丹参酮ⅡA磺酸钠分别联合依达拉奉治疗急性缺血性脑梗死的药物经济学效果。方法：运用回顾性调查法，筛选出符合要求的61例急性缺血性脑梗死患者，采取的用药方案为A组（银杏达莫＋依达拉奉）19例、B组（脉络宁＋依达拉奉）21例、C组（丹参酮ⅡA磺酸钠＋依达拉奉）21例，14 d后观察各组疗效并计算治疗成本，进行药物经济学评价。结果：A组、B组、C组治疗急性缺血性脑梗死的成本分别为7964.88元、7012.81元、9636.82元；成本-效果比分别为94.55、105.19、120.91。结论：与B组和C组相比，A组是治疗急性缺血性脑梗死的最佳用药方案。
目的：探討銀杏達莫、脈絡寧和丹參酮ⅡA磺痠鈉分彆聯閤依達拉奉治療急性缺血性腦梗死的藥物經濟學效果。方法：運用迴顧性調查法，篩選齣符閤要求的61例急性缺血性腦梗死患者，採取的用藥方案為A組（銀杏達莫＋依達拉奉）19例、B組（脈絡寧＋依達拉奉）21例、C組（丹參酮ⅡA磺痠鈉＋依達拉奉）21例，14 d後觀察各組療效併計算治療成本，進行藥物經濟學評價。結果：A組、B組、C組治療急性缺血性腦梗死的成本分彆為7964.88元、7012.81元、9636.82元；成本-效果比分彆為94.55、105.19、120.91。結論：與B組和C組相比，A組是治療急性缺血性腦梗死的最佳用藥方案。
목적：탐토은행체막、맥락저화단삼동ⅡA광산납분별연합의체랍봉치료급성결혈성뇌경사적약물경제학효과。방법：운용회고성조사법，사선출부합요구적61례급성결혈성뇌경사환자，채취적용약방안위A조（은행체막＋의체랍봉）19례、B조（맥락저＋의체랍봉）21례、C조（단삼동ⅡA광산납＋의체랍봉）21례，14 d후관찰각조료효병계산치료성본，진행약물경제학평개。결과：A조、B조、C조치료급성결혈성뇌경사적성본분별위7964.88원、7012.81원、9636.82원；성본-효과비분별위94.55、105.19、120.91。결론：여B조화C조상비，A조시치료급성결혈성뇌경사적최가용약방안。
Objective: To observe the pharmacoeconomic effects of Ginkgo Leaf Extract and Dipyri-damole injection, Mailuoning injection and Tanshinone ⅡA Sulfonic Acid Natrium injection, joined up with Edaravone injection separately, for acute ischemic cerebral infarction(ACI). Methods: A total of 61 cases of ACI were divided into group A (Ginkgo Leaf Extract and Dipyridamole injection + Edaravone injection), 19; group B (Mailuoning injection + Edaravone injection), 21; and group C (Tanshinone ⅡA Sulfonic Acid Natrium injection+ Edaravone injection), 21. The curative efficacies were observed to analyze cost-effective-ness after 14 days of treatment. Results: The costs of group A, B and C were RMB 7964.88, 7012.81 and 9636.82 yuan, respectively. The cost-effectiveness ratios were 94.55, 105.19 and 120.91, respectively. Con-clusion: Compared with Group B and Group C,Group A is the optimal regime in the treatment of ACI.
